Generic Medicine Info
Terazosin: May be taken with or without food.
History of micturition syncope in the treatment of BPH.
Special Precautions
Patient with permanent erectile dysfunction and male impotence; severe coronary heart disease, pulmonary oedema due to aortic or mitral valve stenosis, high output cardiac insufficiency, right-sided cardiac insufficiency due to pulmonary embolism or pericardial effusion, left-sided cardiac insufficiency with low filling pressure. Hepatic impairment. Pregnancy and lactation. Patient Counselling This drug may cause dizziness, drowsiness, and visual disturbances, if affected, do not drive or operate machinery. Monitoring Parameters Monitor blood pressure. Rule out prostate cancer before starting therapy for benign prostatic hyperplasia (BPH).
Adverse Reactions
Significant: First-dose hypotensive episodes (e.g. postural hypotension, syncope), orthostatic hypotension, priapism, floppy iris syndrome during cataract surgery, drowsiness, somnolence. Blood and lymphatic system disorders: Thrombocytopenia. Cardiac disorders: Palpitations, tachycardia, arrythmia, atrial fibriliation, chest pain. Endocrine disorders: Tinnitus. Eye disorders: Blurred vision, amblyopia, visual impairment, conjunctivitis. General disorders and administration site conditions: Asthenia, pyrexia, flu symptoms. Immune system disorders: Anaphylactoid reaction, angioedema, face oedema. Investigations: Weight increased, decreased hematocrit, decreased Hb, decreased WBC count, decreased total protein, decreased blood albumin. Metabolism and nutrition disorders: Peripheral oedema, oedema, Musculoskeletal and connective tissue disorders: Back pain, pain in extremity, neck pain, shoulder pain, gout, arthralgia, arthritis, joint disorders, myalgia. Nervous system disorders: Headache, paraesthesia, vertigo. Psychiatric disorders: Depression, nervousness, anxiety, insomnia. Renal and urinary disorders: Pollakiuria, UTI, urinary incontinence. Reproductive system and breast disorders: Libido decreased, erectile dysfunction. Respiratory, thoracic and mediastinal disorders: Nasal congestion, rhinitis, dyspnea, sinusitis, bronchitis, pharyngitis, cold symptoms, cough. Skin and subcutaneous tissue disorders: Pruritus, rash, hyperhidrosis. Vascular disorders: Vasodilation, epistaxis.
Drug Interactions
Increased adverse effects with ACE inhibitors (e.g. captopril, enalapril); and diuretics (e.g. hydrochlorothiazide, furosemide). Additive hypotensive effect with other antihypertensive agents. Increased concentration and significant hypotension with verapamil. Additive blood pressure lowering effect and symptomatic hypotension with phosphodiesterase type 5 (PDE5) inhibitors (e.g. sildenafil, tadalafil).
CIMS Class
Drugs for Bladder & Prostate Disorders / Other Antihypertensives
ATC Classification
G04CA03 - terazosin ; Belongs to the class of alpha-adrenoreceptor antagonists. Used in the treatment of benign prostatic hypertrophy.
Disclaimer: This information is independently developed by CIMS based on terazosin from various references and is provided for your reference only. Therapeutic uses, prescribing information and product availability may vary between countries. Please refer to CIMS Product Monographs for specific and locally approved prescribing information. Although great effort has been made to ensure content accuracy, CIMS shall not be held responsible or liable for any claims or damages arising from the use or misuse of the information contained herein, its contents or omissions, or otherwise. Copyright © 2021 CIMS. All rights reserved. Powered by CIMSAsia.com
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in